摘要
目的探讨肝病患者血清CA19-9水平变化及其临床意义。方法采用放射免疫法分析测定30例肝病患者(12例慢性肝炎,1例急性肝炎,10例肝硬化,3例自身免疫性肝炎和4例肝衰竭)发病过程中和肝功能恢复时血清中CA19-9水平,腹部彩超检查排除肝脏和胰腺恶性肿瘤。结果CA19-9总阳性率为83.33%(25/30),其中CA19-9水平大多在正常值上限到1～30倍(24/25)。血清CA19-9水平与血清总胆红素呈正相关(P<0.05),并且随着肝功能的恢复而降到正常范围。所有患者未发现肝脏和胰腺肿瘤。结论肝病患者血清CA19-9水平常处于高水平,因此CA19-9升高并不完全是肝脏和胰腺肿瘤存在的指标。
Objective To observe the serum levels of CA19-9 in liver disease patients and their clinical significance. Methods Serum levels of CA19-9 were determined with RIA in 30 patients among whom there were 12 patients with chronic hepatitis, 1 patient with acute hepatitis, 10 with cirrhosis of liver,3 with autoimmune hepatitis and 4 with hepatic failure （3 with chronic severe hepatitis B and 1 with hepatolentieular degeneration）. Results The total positive rate Of CA19-9 was 83.33%（25/ 30）, and among most of the patients the CA19-9 levels were from IxULN （upper limit of normal） to 30×ULN（72%, 24/25）. The serum level of CA19-9 was positively related to the levels of serum bilirubin （,~〈0.05）. Conclusion Serum CA19-9 being at high levels in patients with liver disease is very popular.The CA19-9 determination is not helpful for the exclusive dianosis of pancreatic and liver malignancies.
出处
《实用医药杂志》
2008年第9期1043-1044,共2页
Practical Journal of Medicine & Pharmacy
